Reven Stock

reven.comBioTechFounded: 1999Funding to Date: $106.23MM

Reven Pharmaceuticals is a biopharmaceutical company developing solutions for those suffering the effects of vascular and metabolic related diseases.

Register for Details

For more details on financing and valuation for Reven, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Peter Lange
Founder, Board Member & Chief Executive Officer
Michael Volk
Chief Financial Officer & Board Member
Brian Denomme
Chief Operating Officer & Board Member
James Ervin
Chief Technology Officer
Henk Van Wyk
Chief Scientist

Board Members

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
Peter Lange
Founder, Board Member & Chief Executive Officer

Other companies like Reven in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

New Delhi, India -- (SBWIRE) -- 04/09/2018 -- Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD). It occurs with severe obstructions in the arteries which leads to reduced blood flow to the extremities.
There has been $13.1 billion invested across 1,287 deals so far this year